{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=49&state=Ohio", "query": { "state": "Ohio", "city": "Columbus", "page": 49 }, "page_size": 10 }, "pagination": { "page": 49, "page_size": 10, "total_count": 10856, "total_pages": 1086, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=50&state=Ohio&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=48&state=Ohio&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T20:47:29.010Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04287985", "title": "Safety and Efficacy Study of VIS649 for IgA Nephropathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Immunoglobulin A Nephropathy", "Glomerular Disease", "IgAN" ], "interventions": [ { "name": "Dose-Placebo", "type": "DRUG" }, { "name": "Low Dose-VIS649", "type": "DRUG" }, { "name": "Medium Dose-VIS649", "type": "DRUG" }, { "name": "High Dose-VIS649", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2020-07-20", "completion_date": "2023-06-18", "has_results": true, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-11-09T20:47:29.010Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Los Angeles, California • Oxnard, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04287985" }, { "nct_id": "NCT04578925", "title": "Happy, Healthy, Loved: A Mobile-delivered Breastfeeding Self-efficacy Intervention for First Time Parents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Feeding" ], "interventions": [ { "name": "Happy, Healthy, Loved", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "OhioHealth", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 128, "start_date": "2020-10-01", "completion_date": "2023-03-01", "has_results": false, "last_update_posted_date": "2023-07-14", "last_synced_at": "2026-11-09T20:47:29.010Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04578925" }, { "nct_id": "NCT03839940", "title": "Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Malignant Neoplasm" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Questionnaire", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2019-06-03", "completion_date": "2022-08-03", "has_results": true, "last_update_posted_date": "2025-01-29", "last_synced_at": "2026-11-09T20:47:29.010Z", "location_count": 319, "location_summary": "Birmingham, Alabama • Kingman, Arizona • Fort Smith, Arkansas + 198 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Kingman", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Arroyo Grande", "state": "California" }, { "city": "Dublin", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03839940" }, { "nct_id": "NCT01872689", "title": "A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "Lebrikizumab", "type": "DRUG" }, { "name": "Pirfenidone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 505, "start_date": "2013-10-13", "completion_date": "2017-11-06", "has_results": true, "last_update_posted_date": "2018-08-24", "last_synced_at": "2026-11-09T20:47:29.010Z", "location_count": 54, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01872689" }, { "nct_id": "NCT00005089", "title": "S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2000-04", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2017-01-16", "last_synced_at": "2026-11-09T20:47:29.010Z", "location_count": 92, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005089" }, { "nct_id": "NCT06576271", "title": "A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "GSK4527363", "type": "DRUG" }, { "name": "Placebo matching GSK4527363", "type": "DRUG" }, { "name": "Belimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 142, "start_date": "2024-09-02", "completion_date": "2028-01-11", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-11-09T20:47:29.010Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Las Vegas, Nevada + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT06576271" }, { "nct_id": "NCT04439006", "title": "Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Aplastic Anemia", "Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm", "Monoclonal B-Cell Lymphocytosis", "Monoclonal Gammopathy of Undetermined Significance", "Myelodysplastic Syndrome", "Symptomatic COVID-19 Infection Laboratory-Confirmed" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Jennifer Woyach", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2020-10-23", "completion_date": "2022-09-20", "has_results": false, "last_update_posted_date": "2023-12-26", "last_synced_at": "2026-11-09T20:47:29.010Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04439006" }, { "nct_id": "NCT00970606", "title": "STIP: Statin Trial for Influenza Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Respiratory Distress Syndrome", "Influenza", "H1N1 Influenza" ], "interventions": [ { "name": "Rosuvastatin (crestor)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gordon Bernard", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 7, "start_date": "2009-10", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2017-03-22", "last_synced_at": "2026-11-09T20:47:29.010Z", "location_count": 21, "location_summary": "Little Rock, Alaska • Phoenix, Arizona • Stanford, California + 17 more", "locations": [ { "city": "Little Rock", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00970606" }, { "nct_id": "NCT00911326", "title": "Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma (HNSCC)" ], "interventions": [ { "name": "Lymphoseek", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Navidea Biopharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2009-05", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2014-08-08", "last_synced_at": "2026-11-09T20:47:29.010Z", "location_count": 13, "location_summary": "Birminham, Alabama • La Jolla, California • San Diego, California + 10 more", "locations": [ { "city": "Birminham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00911326" }, { "nct_id": "NCT00551135", "title": "Surgical Pain After Inguinal Hernia Repair (SPAIHR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pain, Postoperative", "Hernia, Inguinal" ], "interventions": [ { "name": "Pregabalin", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": "75 Years", "sex": "MALE", "summary": "17 Years to 75 Years · Male only" }, "enrollment_count": 425, "start_date": "2008-01", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2021-01-25", "last_synced_at": "2026-11-09T20:47:29.010Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Glendale, California • Laguna Hills, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Lake Worth", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00551135" } ] }